FERM domain containing 8Genealiases: FKSG44 · iTAP
Q-omics provides the consensus-scored FRMD8 profile across patient tissues and cancer cell-line models. FRMD8 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, FRMD8 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, FRMD8 protein abundance shows 23,123 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LIHC, KIRC, and PDAC as cancer lineages where FRMD8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRMD8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRMD8 survival associations across molecular data types. FRMD8 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRMD8 RNA expression–survival associations across cancer types. High FRMD8 expression shows unfavorable associations in LIHC, LGG, UVM and LUAD, but favorable associations in KIRC and UCS. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for FRMD8 RNA expression.
This table summarizes FRMD8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FRMD8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRMD8 shows higher tumor expression in KIRC, HNSC, LIHC, STAD, BRCA and LUSC. The KIRC box plot shows higher FRMD8 RNA expression in tumor versus normal tissue (log2 FC = +1.038, t-test p < 0.001).
This table shows molecular features associated with FRMD8 in patient tissues and cancer cell lines. In patient samples, FRMD8 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, FRMD8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUAD.
